Expression of EZH2 in uveal melanomas patients and associations with prognosis

PURPOSE: To analyze the prognostic value and potential target for therapeutic intervention of enhancer of zeste homologue 2 (EZH2) in uveal melanomas (UM) patients. METHOD: We analyzed EZH2 expression in 89 primary UM patients by immuno- histochemistry to observe the clinicopathological and prognost...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Ying, Li, Ying, Huang, Xin, Wei, Wenbin, Qu, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652716/
https://www.ncbi.nlm.nih.gov/pubmed/29100322
http://dx.doi.org/10.18632/oncotarget.19462
Descripción
Sumario:PURPOSE: To analyze the prognostic value and potential target for therapeutic intervention of enhancer of zeste homologue 2 (EZH2) in uveal melanomas (UM) patients. METHOD: We analyzed EZH2 expression in 89 primary UM patients by immuno- histochemistry to observe the clinicopathological and prognostic value of EZH2. RESULTS: The high levels of mitoses count and Ki67 labeling index had significant correlation with overexpression EZH2 (R = 0.408, P CONCLUSION: Our critical finding is that overexpression EZH2 in UM can be served as predictive marker and is associated with adverse clinical outcomes. Further observation of EZH2 as a potential therapeutic target in UM is necessary.

Ejemplares similares